To evaluate the potential associations between SPARCL1 polymorphisms and clinical variables, ANOVA was performed after dividing participants into three groups: ischemic stroke patients and controls (Table S5), control group (Table S6), and ischemic stroke patients (Table S7). Here, SPARCL1 is linked to ischemic stroke.